Age (years) | 68 (9.5) | 67.1 (10.1) | |
Men/women | 69.3%/30.7% | 75%/25% | |
Rhythm | | | |
Atrial fibrillation | 365 | 208 | |
Atrial flutter | 3 | 2 | |
Cause of atrial fibrillation | | | |
Coronary artery disease | 55 (14.9%) | 24 (11.4%) | 0.25* |
Hypertension | 163 (44.2%) | 74 (35.2%) | 0.041 |
Congestive cardiomyopathy | 25 (6.8%) | 8 (3.8%) | 0.144* |
Valvar heart disease | 21(5.7%) | 22 (10.5%) | 0.033 |
Post-cardiac surgery | 33 (8.9%) | 20 (9.5%) | 0.796* |
Sick sinus syndrome | 7 (1.9%) | 6 (2.8%) | 0.446* |
Idiopathic | 41 (11.1%) | 22 (10.5%) | 0.835* |
Hyperthyroidism | 4 (1.1%) | 1 (0.5%) | 0.451* |
ASD (after Amplatz closure) | 2 (0.5%) | 2 (1.0%) | 0.562* |
Not recorded | 17 (4.6%) | 31 (14.8%) | |
Duration of atrial fibrillation (months) |
0–6 | 112 (30.4%) | 11 (5.2%) | <0.0001 |
6–12 | 150(40.8%) | 36 (17.1%) | <0.0001 |
>12 | 89 (24.2%) | 136 (64.8%) | <0.0001 |
Not known | 17 (4.6%) | 27 (12.9%) | <0.0001 |
Antiarrhythmic drugs | | | |
β Blockers | 213 (57.9%) | 96 (45.7%) | 0.007 |
Amiodarone | 74 (20.1%) | 18 (8.6%) | <0.0001 |
Digoxin | 137 (37.2%) | 67 (31.9%) | 0.227* |
Flecainide | 13 (3.5%) | 10 (4.8%) | 0.453* |
Calcium antagonists | 98 (26.6%) | 51 (24.2%) | 0.578* |
Propafenone | 1 (0.3%) | 0 | |
Previous cardioversions | 27 (7.33%) | 62 (29.52%) | <0.0001 |